Mega-Rounds Reshape the AI Map: Atoms, AIsphere, and Chai Discovery Lead a Blockbuster Funding Week

A $1.7 billion physical AI round, a $439 million AI video raise backed by Alibaba, and a $400 million AI drug discovery round show capital spreading far beyond chatbots.

A Week That Redrew the AI Funding Map

If you wanted a single week to illustrate exactly how much capital is still pouring into artificial intelligence — and exactly how far that capital now reaches beyond chatbots and coding tools — late July 2026 supplied it. Across a span of roughly ten days, investors backed a humanoid-adjacent physical AI company at a scale usually reserved for public companies, an AI video startup with backing from one of Asia’s largest technology conglomerates, and an AI-driven drug discovery company whose investor list reads like a who’s-who of venture capital’s biggest names. Individually, each round would be a significant story. Together, they sketch the shape of where sophisticated money believes AI is actually going next: out of the browser tab and into hardware, biology, and physical infrastructure.

Atoms: Physical AI’s Biggest Single Bet of the Month

The headline figure belongs to Atoms, a physical AI startup founded by Travis Kalanick, the co-founder and former CEO of Uber. Atoms raised $1.7 billion in a round led by Andreessen Horowitz, one of the largest single checks written for a physical AI company so far in 2026. The scale of the round places Atoms in rarefied company — a tier of funding typically reserved for frontier AI labs building foundation models, not for a company applying AI to physical systems and hardware.

That a company operating outside the pure-software AI stack can command a check of this size says a great deal about where investor conviction is shifting. Physical AI — the fusion of AI models with real-world hardware, robotics, perception systems, and industrial automation — has been one of the fastest-growing investment categories of 2026, and Kalanick’s name recognition undoubtedly helps Atoms attract capital and attention that a less prominent founder might struggle to match. But the size of this particular round suggests investors are betting on more than a famous founder; they are betting that the physical AI category as a whole is entering the stage where mega-rounds, once reserved for language model labs, become normal.

AIsphere: Alibaba Backs a New Contender in AI Video

A few days earlier, AIsphere closed a $439 million Series C round led by Alibaba Group Holding, with the round completed on July 14 and publicly disclosed the following day. AIsphere’s focus is AI video generation, a category that has become one of the most fiercely contested corners of the generative AI market over the past two years, as models capable of producing increasingly convincing, controllable video content move from research demos into commercial products used by studios, advertisers, and independent creators.

Alibaba’s decision to lead a round of this size is notable for two reasons. First, it reflects the increasingly global nature of AI video competition: American labs, Chinese technology conglomerates, and independent startups are all racing toward the same underlying capability, and Alibaba’s involvement signals that Chinese capital and infrastructure are prepared to back ambitious, well-funded challengers in the space rather than ceding the category to U.S.-based incumbents. Second, the scale of the round — nearly half a billion dollars in a single Series C — underscores how capital-intensive AI video generation remains relative to text-based AI products; training and serving high-quality video models requires substantially more compute than equivalent-scale language models, and investors backing this category are, in effect, also betting on continued access to large-scale compute infrastructure.

Chai Discovery: When AI Drug Development Attracts a Rare Investor Coalition

The third major round of the stretch came from Chai Discovery, an AI drug development company that closed a $400 million Series C, also announced on July 14. What sets this round apart from a typical biotech financing is not just the size, but the composition of the investor syndicate: lead investors included Index Ventures, Kleiner Perkins, Sequoia Capital, and Dimension, with additional participation from Bain Capital Ventures, Thrive Capital, Yosemite, and — notably — OpenAI itself.

OpenAI’s participation as a co-investor in an AI drug discovery company is a small detail with outsized significance. It signals that the frontier labs building general-purpose foundation models are no longer content to simply license or license out their technology to specialized applied-AI companies; they are increasingly choosing to take direct equity positions in the companies applying AI to high-value, high-complexity scientific domains like drug discovery. For Chai Discovery, that kind of backing brings more than capital — it potentially brings early access to frontier model capabilities and a signal to the broader biotech and pharmaceutical industry that one of the most closely watched AI labs in the world believes in the company’s scientific approach.

Drug discovery has long been held up as one of the most promising, and most difficult, applications of AI: promising because the potential value of accelerating the identification of viable drug candidates is enormous, and difficult because biological systems are messier, noisier, and far less forgiving of model error than text or image generation. A $400 million round with this investor coalition suggests that some of venture capital’s most disciplined firms believe the technical and scientific risk in this space has become manageable enough to justify a nine-figure bet.

The Bigger Pattern: Concentration, Physical AI, and a Widening Definition of “AI Company”

Zoom out from these three individual rounds, and a broader story about 2026’s venture capital environment comes into focus. The first half of 2026 already set records for global venture funding, with the overwhelming majority of that capital flowing specifically into AI-related companies, and a striking share of it concentrated in a small handful of frontier labs. Against that backdrop, weeks like this one matter because they show the capital spreading — not away from AI, but into new sub-categories within it: physical systems and robotics, video generation infrastructure, and computational biology.

Three trends stand out across the week’s biggest deals:

• Physical AI has arrived as a mega-round category. Atoms’ $1.7 billion round shows that AI applied to physical systems can now attract the kind of capital previously reserved almost exclusively for foundation model labs.
• Geography is no longer a limiting factor for capital sources. Alibaba’s lead role in AIsphere’s round is a reminder that AI video, and generative AI more broadly, is being bankrolled by a genuinely global set of investors, not solely U.S. venture funds.
• Frontier labs are becoming venture investors in applied AI. OpenAI’s participation in Chai Discovery’s round follows a pattern seen elsewhere in 2026, where the largest AI labs increasingly place direct bets on the companies building specialized applications on top of, or adjacent to, their own research.

What Comes Next

For founders building in adjacent categories, the message from this week’s rounds is fairly direct: the largest checks in AI are no longer reserved for whoever is training the biggest general-purpose model. Investors are increasingly willing to write nine- and ten-figure checks for teams that can demonstrate a credible, differentiated application of AI in a specific, high-value domain — whether that domain is humanoid or industrial robotics, high-fidelity video generation, or computational drug discovery.

For the broader industry, it is also worth watching how these three companies deploy their new capital over the coming quarters. Atoms will need to show that $1.7 billion in physical AI funding translates into deployable products rather than an extended research phase. AIsphere will be tested by how quickly it can differentiate itself in an AI video market that already includes well-funded competitors from multiple countries. And Chai Discovery’s real test will not be its funding round at all, but whether its AI-driven approach to drug discovery can produce a genuine clinical candidate — the kind of result that would validate not just this one company, but the broader thesis that AI-native firms with elite investor backing can meaningfully compress the drug development timeline.

None of that is guaranteed. But the fact that investors are willing to make these bets at this scale, across such different domains, in the same ten-day window, is itself a signal that the next phase of the AI boom is unlikely to be defined by any single category. It will be defined by how far AI’s economic footprint can stretch — into factories, into video production, and into the laboratory.

A Note on Valuation Discipline

One question worth asking about any week featuring multiple mega-rounds is whether the sizes reflect underlying business fundamentals or simply reflect how much dry powder venture firms are currently sitting on. The honest answer is probably both. Venture capital raised specifically for AI investments has grown so large, and so concentrated among a handful of firms competing for a limited number of credible deals, that valuations across the sector have been pushed upward independent of any single company’s revenue or product maturity. That dynamic makes it harder to use round size alone as a signal of quality; a $400 million or $1.7 billion check reflects as much about investor competition for access as it does about a startup’s demonstrated traction.

That caveat matters for anyone trying to read these three deals as pure signal. Atoms, AIsphere, and Chai Discovery are each, in their own way, unproven at the scale their funding implies — Atoms is still building out its physical AI product line, AIsphere is entering a crowded and rapidly evolving video generation market, and Chai Discovery’s scientific approach has yet to produce a marketed drug. What the rounds do reliably signal is investor conviction, not commercial certainty. Distinguishing between the two will be the job of the next several quarters, not this week’s headlines.